Puma Biotechnology, Inc. (PBYI) Financial Ratios
19 years of historical data (2007–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
7.64
+6% vs avg
5yr avg: 7.20
30Y Low3.6·High14.1
P/FCF
↑
8.85
+13% vs avg
5yr avg: 7.85
30Y Low3.9·High15.4
P/B Ratio
↓
2.82
↓-32% vs avg
5yr avg: 4.15
30Y Low1.6·High68.9
ROE
↑
28.0%
-12% vs avg
5yr avg: 31.8%
30Y Low-292%·High58%
Debt/EBITDA
↓
0.59
↓-83% vs avg
5yr avg: 3.51
30Y Low0.6·High9.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PBYI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Puma Biotechnology, Inc. trades at 11.9x earnings, 80% below its 5-year average of 58.2x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 47%. On a free-cash-flow basis, the stock trades at 8.9x P/FCF, 13% above the 5-year average of 7.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $369M | $301M | $150M | $206M | $190M | $124M | $406M | $339M | $772M | $3.7B | $1.0B |
| Enterprise Value | $368M | $300M | $155M | $233M | $228M | $177M | $442M | $399M | $816M | $3.6B | $828M |
| P/E Ratio → | 11.90 | 9.75 | 4.92 | 9.62 | 208.37 | — | — | — | — | — | — |
| P/S Ratio | 1.62 | 1.32 | 0.65 | 0.87 | 0.83 | 0.49 | 1.80 | 1.25 | 3.08 | 132.64 | — |
| P/B Ratio | 2.82 | 2.31 | 1.63 | 3.85 | 8.80 | — | — | 19.43 | 22.51 | 68.93 | 4.87 |
| P/FCF | 8.85 | 7.22 | 3.85 | 14.33 | — | 5.98 | — | 15.37 | — | — | — |
| P/OCF | 8.84 | 7.21 | 3.85 | 7.62 | — | 5.98 | 507.56 | 15.16 | — | — | — |
P/E links to full P/E history page with 30-year chart
PBYI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Puma Biotechnology, Inc.'s enterprise value stands at 7.6x EBITDA, 6% above its 5-year average of 7.2x. The Healthcare sector median is 14.4x, placing the stock at a 47% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.31 | 0.67 | 0.99 | 1.00 | 0.70 | 1.96 | 1.47 | 3.25 | 131.44 | — |
| EV / EBITDA | 7.64 | 6.23 | 3.64 | 5.27 | 6.80 | 14.06 | — | — | — | — | — |
| EV / EBIT | 9.88 | 7.08 | 4.23 | 6.47 | 18.93 | — | — | — | — | — | — |
| EV / FCF | — | 7.20 | 3.98 | 16.20 | — | 8.57 | — | 18.10 | — | — | — |
PBYI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Puma Biotechnology, Inc. earns an operating margin of 16.3%. Operating margins have expanded from 13.9% to 16.3% over the past 3 years, signaling improving operational efficiency. ROE of 28.0% indicates solid capital efficiency. ROIC of 24.7% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.5% | 74.5% | 72.1% | 73.4% | 75.8% | 74.8% | 82.5% | 86.5% | 86.2% | 79.8% | — |
| Operating Margin | 16.3% | 16.3% | 13.4% | 13.9% | 10.4% | 0.5% | -13.5% | -27.8% | -37.7% | -1055.6% | — |
| Net Profit Margin | 13.6% | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | -26.7% | -27.8% | -45.3% | -1054.2% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 28.0% | 28.0% | 41.6% | 57.5% | 0.0% | — | -1042.3% | -292.0% | -259.3% | -222.0% | -132.8% |
| ROA | 14.5% | 14.5% | 13.6% | 9.5% | 0.0% | -12.4% | -25.0% | -30.6% | -53.5% | -139.6% | -112.1% |
| ROIC | 24.7% | 24.7% | 26.2% | 35.0% | 32.1% | 2.4% | -42.5% | -72.9% | -145.1% | -1239.8% | -218.7% |
| ROCE | 29.6% | 29.6% | 24.9% | 23.7% | 18.1% | 1.0% | -22.2% | -45.0% | -63.3% | -181.3% | -130.9% |
PBYI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Puma Biotechnology, Inc. carries a Debt/EBITDA ratio of 0.6x, which is very conservative (82% below the sector average of 3.3x). The company holds a net cash position — cash of $30M exceeds total debt of $29M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 6.4x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.80 | 2.09 | 5.29 | — | — | 6.88 | 4.43 | 0.91 | — |
| Debt / EBITDA | 0.59 | 0.59 | 1.74 | 2.52 | 3.41 | 9.26 | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | 0.05 | 0.50 | 1.76 | — | — | 3.45 | 1.27 | -0.62 | -0.93 |
| Net Debt / EBITDA | -0.02 | -0.02 | 0.11 | 0.61 | 1.13 | 4.25 | — | — | — | — | — |
| Debt / FCF | — | -0.03 | 0.13 | 1.87 | — | 2.59 | — | 2.73 | — | — | — |
| Interest Coverage | 6.40 | 6.40 | 2.94 | 2.70 | 1.04 | -1.25 | -3.26 | -4.03 | -9.33 | -404.49 | -288.72 |
Net cash position: cash ($30M) exceeds total debt ($29M)
PBYI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Puma Biotechnology, Inc.'s current ratio of 2.00x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.57x to 2.00x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.00 | 2.00 | 1.54 | 1.57 | 1.73 | 1.28 | 1.28 | 1.83 | 3.02 | 1.82 | 6.31 |
| Quick Ratio | 1.93 | 1.93 | 1.45 | 1.50 | 1.67 | 1.21 | 1.25 | 1.80 | 2.99 | 1.79 | 6.31 |
| Cash Ratio | 1.20 | 1.20 | 1.05 | 0.97 | 1.05 | 0.75 | 0.82 | 1.23 | 1.62 | 1.40 | 5.19 |
| Asset Turnover | — | 1.06 | 1.08 | 1.02 | 1.03 | 1.12 | 0.92 | 1.16 | 0.97 | 0.17 | — |
| Inventory Turnover | 10.55 | 10.55 | 7.38 | 8.85 | 12.17 | 8.96 | 11.40 | 11.61 | 13.18 | 2.76 | — |
| Days Sales Outstanding | — | 85.75 | 50.70 | 75.11 | 67.66 | 46.90 | 41.42 | 38.74 | 31.92 | 127.42 | — |
PBYI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Puma Biotechnology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 8.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.4% | 10.3% | 20.3% | 10.4% | 0.5% | — | — | — | — | — | — |
| FCF Yield | 11.3% | 13.8% | 26.0% | 7.0% | — | 16.7% | — | 6.5% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $51M | $49M | $48M | $45M | $41M | $40M | $39M | $38M | $37M | $33M |
Peer Comparison
Compare PBYI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PBYIYou | $369M | 11.9 | 7.6 | 8.9 | 74.5% | 16.3% | 28.0% | 24.7% | 0.6 |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 EXEL | $12B | 16.6 | 12.7 | 13.9 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 AZN | $283B | 27.9 | 15.8 | 24.1 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 MCK | $92B | 29.2 | 18.7 | 17.6 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 19 years · Updated daily
See PBYI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PBYI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PBYI vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonPBYI — Frequently Asked Questions
Quick answers to the most common questions about buying PBYI stock.
What is Puma Biotechnology, Inc.'s P/E ratio?
Puma Biotechnology, Inc.'s current P/E ratio is 11.9x. The historical average is 8.1x. This places it at the 100th percentile of its historical range.
What is Puma Biotechnology, Inc.'s EV/EBITDA?
Puma Biotechnology, Inc.'s current EV/EBITDA is 7.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.2x.
What is Puma Biotechnology, Inc.'s ROE?
Puma Biotechnology, Inc.'s return on equity (ROE) is 28.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -88.6%.
Is PBYI stock overvalued?
Based on historical data, Puma Biotechnology, Inc. is trading at a P/E of 11.9x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Puma Biotechnology, Inc.'s profit margins?
Puma Biotechnology, Inc. has 74.5% gross margin and 16.3% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Puma Biotechnology, Inc. have?
Puma Biotechnology, Inc.'s Debt/EBITDA ratio is 0.6x, indicating low leverage. A ratio below 2x is generally considered financially healthy.